Inventor · disambiguated record
Mark K. Bennett
Also filed as: BENNETT MARK · BENNETT MARK K
35 granted patents·21 pending applications·296 citations·filing 2002–2021
97Inventor score
Files withRIGEL PHARMACEUTICALS INC22ONYX THERAPEUTICS INC14CALITHERA BIOSCIENCES INC6PROTEOLIX INC4SHENK KEVIN D3
Top patents by PatentIndex Score
56 records- 0198US7691852B2Compounds for enzyme inhibitionONYX THERAPEUTICS INC·Filed 2007·Granted Apr 6, 2010·65 cites·4 claims
- 0297US8431571B2Compounds for enzyme inhibitionONYX THERAPEUTICS INC·Filed 2012·Granted Apr 30, 2013·33 cites·46 claims
- 0397US8357683B2Compounds for enzyme inhibitionONYX THERAPEUTICS INC·Filed 2011·Granted Jan 22, 2013·34 cites·22 claims
- 0496US8080576B2Compounds for enzyme inhibitionSHENK KEVIN D·Filed 2010·Granted Dec 20, 2011·37 cites·30 claims
- 0596US8080545B2Compounds for enzyme inhibitionSHENK KEVIN D·Filed 2010·Granted Dec 20, 2011·35 cites·17 claims
- 0693US9511109B2Combination therapy with peptide epoxyketonesONYX THERAPEUTICS INC·Filed 2014·Granted Dec 6, 2016·10 cites·5 claims
- 0790US8609654B1Compounds for enzyme inhibitionONYX THERAPEUTICS INC·Filed 2013·Granted Dec 17, 2013·8 cites·60 claims
- 0888US7252952B2In vivo production of cyclic peptides for inhibiting protein—protein interactionRIGEL PHARMACEUTICALS INC·Filed 2003·Granted Aug 7, 2007·19 cites·10 claims
- 0987US7378248B2In vivo production of cyclic peptides for inhibiting protein-protein interactionRIGEL PHARMACEUTICALS INC·Filed 2005·Granted May 27, 2008·7 cites·5 claims
- 1085US7741432B2Substrate for Rpn11 enzymatic activityPROTEOLIX INC·Filed 2006·Granted Jun 22, 2010·8 cites·28 claims
- 1183US10258619B2Combination therapy with glutaminase inhibitors and immuno-oncology agentsCALITHERA BIOSCIENCES INC·Filed 2016·Granted Apr 16, 2019·4 cites·20 claims
- 1283US8895034B2Collagen production compoundBENNETT MARK K·Filed 2011·Granted Nov 25, 2014·10 cites·13 claims
- 1382US9040462B2In vivo production of cyclic peptides for inhibiting protein-protein interactionLORENS JAMES B·Filed 2008·Granted May 26, 2015·5 cites·18 claims
- 1480US7425418B2Compounds that modulate processes associated with IgE productionRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Sep 16, 2008·3 cites·20 claims
- 1578US7071190B2Inhibitors to tubulin polymerizationRIGEL PHARMACEUTICALS INC·Filed 2003·Granted Jul 4, 2006·8 cites·22 claims
- 1676US8765745B2Compounds for enzyme inhibitionONYX THERAPEUTICS INC·Filed 2012·Granted Jul 1, 2014·1 cites·100 claims
- 1768US7563585B2Methods of assaying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein (TXNL)RIGEL PHARMACEUTICALS INC·Filed 2006·Granted Jul 21, 2009·0 cites·11 claims
- 1868US2020254051A1Combination therapy with peptide epoxyketonesONYX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1967US6979549B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 proteinRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Dec 27, 2005·5 cites·52 claims
- 2067US2011236428A1Combination therapy with peptide epoxyketonesONYX THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 2167US2008003620A1Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing an adenosine kinaseRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2266US7604951B2Method for identifying compounds that modulate RXR associated processes with IgE productionRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Oct 20, 2009·1 cites·11 claims
- 2366US7598050B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 proteinRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Oct 6, 2009·1 cites·14 claims
- 2466US2014100169A1Compounds for enzyme inhibitionONYX THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 2566US2014080753A1Compounds for enzyme inhibitionONYX THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 2665US8735441B2Compounds for enzyme inhibitionONYX THERAPEUTICS INC·Filed 2012·Granted May 27, 2014·0 cites·26 claims
- 2765US2021361649A1Combination therapy with glutaminase inhibitors and immuno-oncology agentsCALITHERA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2864US7422867B2Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 proteinRIGEL PHARMACEUTICALS INC·Filed 2007·Granted Sep 9, 2008·0 cites·11 claims
- 2963US10940148B2Combination therapy with glutaminase inhibitors and immuno-oncology agentsCALITHERA BIOSCIENCES INC·Filed 2019·Granted Mar 9, 2021·0 cites·17 claims
- 3062USRE47954ECombination therapy with peptide epoxyketonesONYX THERAPEUTICS INC·Filed 2017·Granted Apr 21, 2020·0 cites·17 claims
- 3162US2003170724A1Methods of identifying target polypeptidesFiled 2002·Application pending·0 cites
- 3261US10596222B2Combination therapy with peptide epoxyketonesONYX THERAPEUTICS INC·Filed 2016·Granted Mar 24, 2020·0 cites·6 claims
- 3361US9657058B2Compounds for enzyme inhibitionONYX THERAPEUTICS INC·Filed 2015·Granted May 23, 2017·0 cites·15 claims
- 3460US7378251B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa proteinRIGEL PHARMACEUTICALS INC·Filed 2002·Granted May 27, 2008·2 cites·28 claims
- 3560US7241581B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC proteinRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Jul 10, 2007·0 cites·20 claims
- 3660US2007135350A1Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IgE Synthesis Utilizing a B-Cell Associated ProteinRIGEL PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 3759US7141434B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinaseRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Nov 28, 2006·0 cites·27 claims
- 3859US2007054862A1Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IgE Synthesis Utilizing an Adenosine KinaseRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 3959US2009215093A1Compounds for enzyme inhibitionPROTEOLIX INC·Filed 2009·Application pending·0 cites
- 4056US2007105140A1In vivo production of cyclic peptidesLORENS JAMES B·Filed 2006·Application pending·0 cites
- 4156US2006276489A1Inhibitors of Tubulin PolymerizationRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4255US8697837B2Substrate for Rpn 11 enzymatic activityPARLATI FRANCESCO·Filed 2009·Granted Apr 15, 2014·0 cites·16 claims
- 4355US7208289B2Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 proteinRIGEL PHARMACEUTICALS INC·Filed 2004·Granted Apr 24, 2007·0 cites·26 claims
- 4455US2008003618A1Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing a b-cell associated proteinRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4554US2007244033A1Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing a c-myc proteinRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4652US2006193844A1Methods for enzyme inhibitionPROTEOLIX INC·Filed 2006·Application pending·0 cites
- 4750US7189523B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated proteinRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Mar 13, 2007·0 cites·29 claims
- 4850US2006088471A1Compounds for enzyme inhibitionPROTEOLIX INC·Filed 2005·Application pending·0 cites
- 4949US7374894B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 proteinRIGEL PHARMACEUTICALS INC·Filed 2002·Granted May 20, 2008·0 cites·28 claims
- 5044US10195197B2Combination therapy with glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2017·Granted Feb 5, 2019·0 cites·17 claims
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mark K. Bennett files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →